Oral GLP-1 Weight-Loss Pills Wegovy and Foundayo Launch in Australia
Australia's first oral GLP-1 weight-loss medications, Wegovy and Foundayo, become available by prescription, offering a daily tablet alternative to injections.
Australia's private-prescription market will see the introduction of oral GLP-1 weight-loss drugs as of Friday, with Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo expected to reach pharmacies in the coming days. The tablets provide a daily alternative to the weekly injectable versions that have been used by more than half a million Australians.
Dr Mark Mellor, chair of the RACGP Specific Interests Obesity Management group, said the new form gives patients more choice and offers practitioners flexibility, particularly for those reluctant to use needles. He noted that about 14 million Australians live with overweight or obesity and many have struggled to achieve lasting results through diet and exercise alone.
Professor Barbara Mintzes, a pharmaceutical policy expert at the University of Sydney, warned that long-term data on GLP-1 use are limited and highlighted concerns about potential nutritional deficiencies, muscle loss in older adults, pancreatitis and a possible increased risk of thyroid cancer. She added that clinical trials often combined the drugs with intensive diet and exercise programs, which may not reflect real-world use.
The Wegovy tablet, approved by the TGA earlier this month, is taken each morning on an empty stomach and is stable at room temperature. Pricing is expected to range from about $260 to $395 per month, translating to under $10 a day for lower doses, making it cheaper than the injectable version, which costs $350-$500 per month.
Foundayo, a small-molecule GLP-1 receptor agonist, can be taken at any time without food or water restrictions and is projected to cost between $250 and $370 per month, depending on dose and pharmacy. Both medicines require a doctor's prescription and may involve out-of-pocket expenses.
Mellor highlighted the high price as an equity issue, noting that obesity disproportionately affects low- and middle-income individuals who may find the drugs unaffordable. Mintzes also raised concerns about “disease awareness” advertising that frames obesity solely as a medical condition, potentially steering consumers toward pharmaceutical solutions while downplaying lifestyle approaches.
The Australian government faces pressure to list GLP-1s for weight loss on the Pharmaceutical Benefits Scheme, a step that could improve accessibility for patients who need the treatment.